Goldman Sachs
BIB icon

Goldman Sachs’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Goldman Sachs’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,246
Closed -$392K – 7075
2014
Q4 		$392K Buy
+6,246
New +$366K ﹤0.01% 5514

Other funds holding BIB

VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return

Goldman Sachs's BIB Position: Q1 2015 in Review

Goldman Sachs sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2015, closing a stake of 6,246 shares — an estimated $392K sold.

Goldman Sachs first reported a position in BIB in Q4 2014 and held it in 1 quarter. The position peaked at $392K in Q4 2014. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2015.

  • Goldman Sachs reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2015 after selling out during the quarter.
  • Goldman Sachs sold 6,246 ProShares Ultra NASDAQ Biotechnology shares in Q1 2015, an estimated $392K.
  • Goldman Sachs first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2014 and held it in 1 quarter.
  • Goldman Sachs's ProShares Ultra NASDAQ Biotechnology position peaked at $392K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2015.

Based on Goldman Sachs's 13F filing for Q1 2015, filed 15 May 2015.